vs
ANI PHARMACEUTICALS INC（ANIP）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是ANI PHARMACEUTICALS INC的1.1倍（$275.3M vs $247.1M），WSFS FINANCIAL CORP净利率更高（31.5% vs 11.1%，领先20.4%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 7.5%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 1.7%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
ANIP vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.1倍
$247.1M
营收增速更快
ANIP
高出22.1%
7.5%
净利率更高
WSFS
高出20.4%
11.1%
两年增速更快
ANIP
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $275.3M |
| 净利润 | $27.5M | $86.8M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | 31.5% |
| 营收同比 | 29.6% | 7.5% |
| 净利润同比 | 367.5% | 31.7% |
| 每股收益（稀释后） | $1.14 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $247.1M | $271.9M | ||
| Q3 25 | $227.8M | $270.5M | ||
| Q2 25 | $211.4M | $267.5M | ||
| Q1 25 | $197.1M | $256.1M | ||
| Q4 24 | $190.6M | $261.5M | ||
| Q3 24 | $148.3M | $267.7M | ||
| Q2 24 | $138.0M | $266.0M |
净利润ANIPWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $27.5M | $72.7M | ||
| Q3 25 | $26.6M | $76.4M | ||
| Q2 25 | $8.5M | $72.3M | ||
| Q1 25 | $15.7M | $65.9M | ||
| Q4 24 | $-10.3M | $64.2M | ||
| Q3 24 | $-24.2M | $64.4M | ||
| Q2 24 | $-2.3M | $69.3M |
营业利润率ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 35.8% | ||
| Q3 25 | 15.9% | 37.3% | ||
| Q2 25 | 6.6% | 35.7% | ||
| Q1 25 | 13.3% | 34.0% | ||
| Q4 24 | -2.3% | 32.3% | ||
| Q3 24 | -13.8% | 31.9% | ||
| Q2 24 | 3.7% | 34.0% |
净利率ANIPWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | 11.1% | 26.7% | ||
| Q3 25 | 11.7% | 28.3% | ||
| Q2 25 | 4.0% | 27.0% | ||
| Q1 25 | 8.0% | 25.7% | ||
| Q4 24 | -5.4% | 24.6% | ||
| Q3 24 | -16.3% | 24.1% | ||
| Q2 24 | -1.7% | 26.0% |
每股收益（稀释后）ANIPWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $1.14 | $1.33 | ||
| Q3 25 | $1.13 | $1.37 | ||
| Q2 25 | $0.36 | $1.27 | ||
| Q1 25 | $0.69 | $1.12 | ||
| Q4 24 | $-0.45 | $1.08 | ||
| Q3 24 | $-1.27 | $1.08 | ||
| Q2 24 | $-0.14 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $2.7B |
| 总资产 | $1.4B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | $1.7B | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | $1.2B | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
股东权益ANIPWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $540.7M | $2.7B | ||
| Q3 25 | $505.8M | $2.8B | ||
| Q2 25 | $436.8M | $2.7B | ||
| Q1 25 | $418.6M | $2.7B | ||
| Q4 24 | $403.7M | $2.6B | ||
| Q3 24 | $405.9M | $2.7B | ||
| Q2 24 | $455.8M | $2.5B |
总资产ANIPWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.4B | $21.3B | ||
| Q3 25 | $1.4B | $20.8B | ||
| Q2 25 | $1.3B | $20.8B | ||
| Q1 25 | $1.3B | $20.5B | ||
| Q4 24 | $1.3B | $20.8B | ||
| Q3 24 | $1.3B | $20.9B | ||
| Q2 24 | $920.8M | $20.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $220.0M | ||
| Q3 25 | $44.1M | $121.5M | ||
| Q2 25 | $75.8M | $37.2M | ||
| Q1 25 | $35.0M | $8.7M | ||
| Q4 24 | $15.9M | $219.9M | ||
| Q3 24 | $12.5M | $3.1M | ||
| Q2 24 | $17.4M | $44.8M |
自由现金流ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $213.6M | ||
| Q3 25 | $38.0M | $120.3M | ||
| Q2 25 | $71.8M | $35.2M | ||
| Q1 25 | $32.5M | $6.3M | ||
| Q4 24 | $13.5M | $205.6M | ||
| Q3 24 | $7.7M | $-489.0K | ||
| Q2 24 | $13.0M | $42.1M |
自由现金流率ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 78.6% | ||
| Q3 25 | 16.7% | 44.5% | ||
| Q2 25 | 34.0% | 13.2% | ||
| Q1 25 | 16.5% | 2.5% | ||
| Q4 24 | 7.1% | 78.6% | ||
| Q3 24 | 5.2% | -0.2% | ||
| Q2 24 | 9.4% | 15.8% |
资本支出强度ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.3% | ||
| Q3 25 | 2.7% | 0.5% | ||
| Q2 25 | 1.9% | 0.7% | ||
| Q1 25 | 1.3% | 0.9% | ||
| Q4 24 | 1.3% | 5.5% | ||
| Q3 24 | 3.2% | 1.4% | ||
| Q2 24 | 3.2% | 1.0% |
现金转化率ANIPWSFS
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 3.03× | ||
| Q3 25 | 1.66× | 1.59× | ||
| Q2 25 | 8.87× | 0.51× | ||
| Q1 25 | 2.23× | 0.13× | ||
| Q4 24 | — | 3.43× | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WSFS
暂无分部数据
